Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Merck
Johnson and Johnson

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

ATACAND Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Drug patent expirations by year for ATACAND
Drug Prices for ATACAND

See drug prices for ATACAND

Recent Clinical Trials for ATACAND

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
BioHealthonomics Inc.Phase 2
Centre Hospitalier Universitaire de Saint EtiennePhase 4

See all ATACAND clinical trials

Synonyms for ATACAND
(+-)-1-Hydroxyethyl 2-ethoxy-1-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methylbenzimidazole-7-carboxylate
(+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methylbenzimidazole-7-carboxylate
040C375
1-(((cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethox
1-(((Cyclohexyloxy)carbonyl)oxy)ethyl 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1-(cyclohexylocarbonyloxy)ethyl-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)-1H-benzimidazole-7-carboxylate
1-(cyclohexyloxycarbonyloxy)ethyl 1-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylate
1-(Cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazol-7-carboxylate
1-[[(cyclohexyloxy)carbonyl]oxy]ethyl 2-ethoxy-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-benzimidazole-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-benzimidazole-7-carboxylate
1-{[(cyclohexyloxy)carbonyl]oxy}ethyl 2-ethoxy-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl] methyl]benzimidazole-4-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate
1-cyclohexyloxycarbonyloxyethyl 2-ethoxy-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate.
145040-37-5
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, ( -)-
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, 1-(((cyclohexyloxy)carbonyl)oxy)ethyl ester, (+-)-
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl ester
1H-Benzimidazolium, 7-carboxy-1-(2-((cyclohexylcarbonyl)oxy)ethyl)-2-ethoxy-1-(2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)-, hydroxide, inner salt, (+-)-
2-ETHOXY-1-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID 1-[[(CYCLOHEXYLOXY)CARBONYL]OXY]ETHYL ESTER
2-Ethoxy-1-[2'-(1H-tetrazole-5-yl)-4-biphenylylmethyl]-1H-benzimidazole-7-carboxylic acid 1-(cyclohexyloxycarbonyloxy)ethyl ester
2-ethoxy-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-benzoimidazole-4-carboxylic acid 1-cyclohe
2-Ethoxy-3-[2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-Ethoxy-3-[2''-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
2-Ethoxy-3-[2''-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3H-benzoimidazole-4-carboxylic acid 1-cyclohexyloxycarbonyloxy-ethyl ester
4CH-009595
A-2005
AB0012012
AB01274805_02
AB01274805_03
AB01274805-01
AB07617
AB2000442
AC-204
AK-75900
AKOS015894954
AKOS015920180
AM90293
Amias
Atacand (TN)
Atacand;Amias;Blopress;Ratacand;TCV 116;TCY 116
BCP22050
BCP9000480
BDBM50318907
BG0573
BR-75900
BRD-A65671304-001-02-6
BRD-A65671304-001-03-4
BSPBio_002691
C-265
C07709
C33H34N6O6
Camptothecine, Antibiotic for Culture Media Use Only
Candesartan (Cilexetil)
Candesartan cilexetil
Candesartan cilexetil (Atacand)
Candesartan cilexetil (JP17/USAN)
Candesartan cilexetil [USAN]
Candesartan cilexetil for peak identification, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil for system suitability, European Pharmacopoeia (EP) Reference Standard
Candesartan cilexetil, >=98% (HPLC)
Candesartan cilexetil, European Pharmacopoeia (EP) Reference Standard
Candesartan Cilexetil, Pharmaceutical Secondary Standard; Certified Reference Material
Candesartan cilexetil, United States Pharmacopeia (USP) Reference Standard
candesartan cilexitil
CANDESARTAN CILEXTIL
Candesartan hexetil
Candesartan-cilexetil-Atacand
candesartancilexetil
CAS-145040-37-5
CCG-222334
CCG-39530
CHEBI:3348
CHEMBL1014
CS-2893
D00626
DB00796
DS-1302
DSSTox_CID_239
DSSTox_GSID_20239
DSSTox_RID_85567
DTXSID5020239
EBD4212
FT-0082579
FT-0602914
GHOSNRCGJFBJIB-UHFFFAOYSA-N
GTPL8352
H212/91
HMS1922J09
HMS2093E20
HMS3651I08
HY-17505
J10436
KBio2_002187
KBio2_004755
KBio2_007323
KBio3_001911
KBioGR_001607
KBioSS_002187
Kenzen
KS-00000IVU
KS-1147
L006257
LS-32741
MFCD00871371
MLS004774127
NCGC00095123-01
NCGC00095123-02
NCGC00095123-03
NCGC00255218-01
NSC-758697
NSC758697
Parapres
Pharmakon1600-01504261
Q-200786
Q27075664
Racanda
s2037
SBI-0206767.P001
SC-12740
SCHEMBL40831
SMR003500784
SPBio_000349
Spectrum_001707
SPECTRUM1504261
Spectrum2_000485
Spectrum3_000996
Spectrum4_001124
Spectrum5_001462
SR-05000001976
SR-05000001976-1
ST24030238
STL451065
SW220041-1
TCV 116
TCV-116
TCY 116
Tox21_302202
VA10473
Paragraph IV (Patent) Challenges for ATACAND
Tradename Dosage Ingredient NDA Submissiondate
ATACAND TABLET;ORAL candesartan cilexetil 020838 2006-12-22

US Patents and Regulatory Information for ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc ATACAND HCT candesartan cilexetil; hydrochlorothiazide TABLET;ORAL 021093-003 May 16, 2008 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ATACAND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-003 Jun 4, 1998   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-004 Jun 4, 1998   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-001 Jun 4, 1998   Start Trial   Start Trial
Ani Pharms Inc ATACAND candesartan cilexetil TABLET;ORAL 020838-002 Jun 4, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for ATACAND

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0459136 SPC/GB97/018 United Kingdom   Start Trial PRODUCT NAME: CANDESARTAN CILEXETIL OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK PL0017/0383 19970429; UK PL0017/0384 19970429; UK PL0017/0385 19970429; UK PL0017/0391 19970429; UK PL15561/0003 19970429; UK PL15661/0001 19970429; UK PL15661/0002 19970429; UK PL15661/0004 19970429
0459136 19875004 Germany   Start Trial PRODUCT NAME: WIRKSTOFF DES ARZNEIMITTELS BLOPRESS BZW. DES ARZNEIMITTELS ATACAND IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; NAT. REGISTRATION NO/DATE: 41261.00.00 41261.01.00 41261.02.00 41261.03.00 41294.00.00 41294.01.00 41294.02.00 41294.03.00 19971203 FIRST REGISTRATION: GROSSBRITANNIEN 15661/0001 15661/0002 15661/0003 15661/0004 19970429
0459136 8/1998 Austria   Start Trial PRODUCT NAME: CANDESARTAN CILEXETIL ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; NAT. REGISTRATION NO/DATE: 1-22232, 1-22233, 1-22235, 1-22236 19971119; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
0459136 C970044 Netherlands   Start Trial PRODUCT NAME: CANDESARTAN, DESGENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT OF VAN DE 1-(CYCLOHEXYLOXYCARBONYLOXY) ETHYLESTE R, IN HET BIJZONDER CILEXETILI CANDESARTANAS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; NAT. REGISTRATION NO/DATE: RVG 21703 - RVG 21706 19971013; FIRST REGISTRATION: GB PL 15661/0001 - PL 15661/0004 19970429
0459136 SZ 8/1998 Austria   Start Trial
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Mallinckrodt
Boehringer Ingelheim
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.